News & Updates
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim data from the ongoing open-label,…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced the first patient has been dosed in the Phase 1 study of FHD-286 in combination with decitabine…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215’s profile as a potential long-acting therapy for hereditary angioedema (HAE) dosed once every three…
Read More
You should not have to compromise your study design simply because your eClinical Technology does not support your unique study requirements. At TrialStat we do things differently. We believe that you should not have to compromise and to make that a reality, we specialize in Custom Validated Development. Whether it’s a small change in workflow,…
Read More
– CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board – – Based on positive results, findings will be discussed with the U.S. Food and Drug Administration – Excerpt from the…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB) infection, today announced the U.S. Food and Drug…
Read More
– Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational therapy in refractory angina – Six-month data have since been sustained out to 12-months supporting durability of XC001 safety and efficacy profile – XC001 targets unmet medical need among patients with refractory angina who have a debilitating quality-of-life burden and no…
Read More
– NB-4746 is being developed as a neuroprotective therapy for neurological diseases – Milestone marks Nura Bio’s transition to a clinical-stage company Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation…
Read More
Excerpt from the Press Release: BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to…
Read More
The biotechnology company aims to offer patients an improved, non-invasive solution for beneath-the-chin body contouring Excerpt from the Press Release: SAN DIEGO, Aug. 16, 2023 /PRNewswire/ — 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today that it has completed enrollment in a repeat treatment study of its…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?